Logo
Nazad
Maud Tusseau, E. Lovšin, C. Samaille, Rémi Pescarmona, M. Maggio, V. Selmanović, M. Debeljak, A. Dachy, A. Janin, Louis Januel, Anne-Laure Mathieu, J. Gibier, Emilie Chopin, I. Rouvet, David Goncalves, N. Fabien, G. Rice, A. Labalme, P. Romagnani, G. Lesca, T. Walzer, S. Viel, M. Perret, Y. Crow, T. Avčin, R. Cimaz, A. Belot
1 24. 5. 2021.

DNASE1L3 Deficiency, New Phenotypes and Evidence for a Transient Type I Interferon Signaling

Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated to a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. Here we report four new patients carrying biallelic DNASE1L3 pathogenic variations, including two previously unreported mutations. Disease in one patient was characterized by lupus nephritis and skin lesions, while two others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented with early-onset inflammatory bowel disease. To explore whether or not the interferon cascade was strongly and sustainably induced, Interferon stimulated genes (ISGs) expression was assessed for each patient. Contrary to canonical type-I interferonopathies, we noticed a transient increase of ISGs in blood, which reverted to normal with disease remission. Reviewing previous reports, DNASE1L3-related disease appears to carry a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). DNASE1L3 deficiency may share the pathogenesis with C1q deficiency by affecting efferocytosis, and this report suggests that interferon production is not directly driven by DNASE1L3 pathogenic variants.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više